Lavan Amanda, Eustace Joseph, Dahly Darren, Flanagan Evelyn, Gallagher Paul, Cullinane Shane, Petrovic Mirko, Perehudoff Katrina, Gudmondsson Adalsteinn, Samuelsson Ólafur, Sverrisdóttir Ástrós, Cherubin Antonio, Dimitri Frederica, Rimland Joe, Cruz-Jentoft Alfonso, Vélez-Díaz-Pallarés Manuel, Lozano Montoya Isabel, Soiza Roy L, Subbarayan Selvarani, O'Mahony Denis
Department of Medicine, University College Cork National University of Ireland, Cork, Ireland.
Department of Epidemiology, University College Cork National University of Ireland, Cork, Ireland.
Ther Adv Drug Saf. 2018 Jan;9(1):13-23. doi: 10.1177/2042098617736191. Epub 2017 Oct 24.
Adverse drug reactions (ADRs) are common in older adults and frequently have serious clinical and economic consequences. This study was conducted as a feasibility study for a randomized control trial (RCT) that will investigate the efficacy of a software engine to optimize medications and reduce incident (in-hospital) ADRs. This study's objectives were to (i) establish current incident ADR rates across the six sites participating in the forthcoming RCT and (ii) assess whether incident ADRs are predictable.
This was a multicentre, prospective observational study involving six European hospitals. Adults aged ⩾ 65 years, hospitalized with an acute illness and on pharmacological treatment for three or more conditions were eligible for inclusion. Adverse events (AEs) were captured using a trigger list of 12 common ADRs. An AE was deemed an ADR when its association with an administered drug was adjudicated as being probable/certain, according to the World Health Organization Uppsala Monitoring Centre causality assessment. The proportion of patients experiencing at least one, probable/certain, incident ADR within 14 days of enrolment/discharge was recorded.
A total of 644 patients were recruited, evenly split by sex and overwhelmingly of White ethnicity. Over 80% of admissions were medical. The median number of chronic conditions was five (interquartile range 4-6), with eight or more conditions present in approximately 10%. The mean number of prescribed medications was 9.9 (standard deviation 3.8), which correlated strongly with the number of conditions ( = 0.54, < 0.0001). A total of 732 AEs were recorded in 382 patients, of which 363 were incident. The majority of events were classified as probably or possibly drug related, with heterogeneity across sites (χ = 88.567, df = 20, value < 0.001). Out of 644 patients, 139 (21.6%; 95% confidence interval 18.5-25.0%) experienced an ADR. Serum electrolyte abnormalities were the most common ADR. The ADRROP (ADR Risk in Older People) and GerontoNet ADR risk scales correctly predicted ADR occurrence in 61% and 60% of patients, respectively.
This feasibility study established the rates of incident ADRs across the six study sites. The ADR predictive power of ADRROP and GerontoNet ADR risk scales were limited in this population.
药物不良反应(ADR)在老年人中很常见,并且经常会产生严重的临床和经济后果。本研究作为一项随机对照试验(RCT)的可行性研究开展,该RCT将调查一款软件引擎优化药物治疗并减少新发(住院期间)ADR的疗效。本研究的目的是:(i)确定即将参与RCT的六个研究地点的当前新发ADR发生率;(ii)评估新发ADR是否可预测。
这是一项涉及六家欧洲医院的多中心前瞻性观察性研究。年龄≥65岁、因急性疾病住院且正在接受三种或更多疾病药物治疗的成年人符合纳入条件。使用包含12种常见ADR的触发清单来记录不良事件(AE)。根据世界卫生组织乌普萨拉监测中心的因果关系评估,当AE与所使用药物的关联被判定为很可能/肯定时,则将该AE视为ADR。记录在入组/出院14天内发生至少一次很可能/肯定的新发ADR的患者比例。
共招募了644例患者,男女比例均衡,绝大多数为白人。超过80%的入院患者为内科疾病。慢性病的中位数为5种(四分位间距4 - 6),约10%的患者存在8种或更多疾病。处方药物的平均数量为9.9种(标准差3.8),与疾病数量密切相关(r = 0.54,P < 0.0001)。共记录到382例患者发生732次AE,其中363次为新发AE。大多数事件被分类为可能或很可能与药物相关,各研究地点存在异质性(χ² = 88.567,自由度 = 20,P值 < 0.001)。在644例患者中,139例(21.6%;95%置信区间18.5 - 25.0%)发生了ADR。血清电解质异常是最常见的ADR。ADRROP(老年人ADR风险)和GerontoNet ADR风险量表分别正确预测了61%和60%患者的ADR发生情况。
这项可行性研究确定了六个研究地点的新发ADR发生率。ADRROP和GerontoNet ADR风险量表在该人群中的ADR预测能力有限。